Demant CEO won't rule out dismissals following divestment of implant division

The 700 people employed at Demant’s surgical division, Oticon Medical, have an uncertain future ahead after the parent company announced its intention to sell the unit to Cochlear. CEO Søren Nielsen says some people might be transferred and others reshuffled within Demant, but he won’t reject having to resort to dismissals.

Photo: Kenneth Lysbjerg Koustrup/Jyllands-Posten/Ritzau Scanpix

If any worried faces were detected this morning among the around 700 people working at the implant division of hearing aid manufacturer Demant, it is well understood why.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs